tradingview.comOCT 271 min read

Exosens (EXENS) Q3 Revenue Up 23.5%; 9M Sales €386.9M

Exosens reported 9-month 2026 revenue of €386.9M, up 18.0% YoY, with Q3 growth at 23.5%. Adjusted gross margin was €194.9M (50.4%). The company stated it is on track to meet its upgraded 2026 guidance.

Original reporting

tradingview.com

Published Oct 27, 2026, 6:15 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 27, 2026, 6:29 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Exosens (EXENS) Q3 Revenue Up 23.5%; 9M Sales €386.9M — source image — Source · tradingview.com

Decision brief

The 30-second read

Med

Why it matters

The earnings beat and raised guidance could prompt short-term buying interest.

Market read

First earnings release for the period, providing fresh data for traders.

What to watch

Currency fluctuations and guidance uncertainty could affect outcomes.

Relevance 7/10Novelty 7/10Timing: today

Background

Exosens released its Q3 2026 results, showing revenue acceleration.

Market effects

Sector

Signals strength in Exosens' sector, potentially boosting peers.

Regional

European tech hardware market may see modest uplift.

Global

Limited to niche market; minimal global effect.

Counterpoint

What could challenge this read

Revenue growth may be unsustainable if demand softens.

Key entities

Company
Exosens
Provider of semiconductor testing equipment.

Read at source ← All news

OCT 27

Med

Why is Exosens stock sliding today?

Exosens stock fell 6% to €56.10 after Q3 2026 revenue growth of 23.5% YoY and 18% for nine months, but investors were disappointed by unchanged guidance and a 50.4% adjusted gross margin. The broader market downturn also contributed to the decline.

investing.com2 min

SEP 17

HighAI 8/10

Why is Exosens stock surging today?

Exosens (EXENS) stock surged 12.1% to €60.90 after revising its 2026 outlook, raising revenue guidance to €558M-€570M from €520M-€540M and EBITDA to €186M-€192M from €168M-€178M. CEO Jerome Cerisier cited faster production ramp-up. No analyst upgrades or insider transactions were reported. The broader market was supportive, with global indices trading higher.

investing.com2 min

AUG 25

Med

Photonis Defense awarded first delivery order for U.S. Army’s BiNOD program, marking a key milestone in Exosens’ U.S. expansion

Exosens' subsidiary, Photonis Defense, received a $1.6B order for 1,600 BiNOD systems from the U.S. Army, marking a key milestone in Exosens' U.S. expansion. Deliveries are expected by the end of 2026, with the bulk in 2027. The order supports the BiNOD program's Low-Rate Initial Production phase, leveraging Photonis Defense's U.S. production capabilities and Exosens' technology leadership. Financial terms were not disclosed.

defenceweb.co.za2 min

JUL 28

Med

Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth

Exosens (EPA: EXENS) reported H1 fiscal 2026 adjusted EBIT of €71m, above the €67m forecast, up 19.2% YoY, with a 28.4% margin. Revenue was €253m, slightly below €254m consensus, but up 11.4% YoY. Q2 revenue was €130.5m. It reaffirmed FY2026 guidance: revenue €520-540m and adjusted EBITDA €168-178m, aiming for upper-end results.

econotimes.com4 min

OCT 28

$RCKYMed

Rocky Brands forecasts 2026 revenue up about 10.5% while raising reported EPS to about $5.30 (NASDAQ:RCKY)

Rocky Brands (RCKY) reported Q3 2026 sales growth of 13%, exceeding expectations. The company forecasts 2026 revenue up about 10.5% and raised EPS guidance to approximately $5.30, according to CEO Jason Brooks.

seekingalpha.com1 min